Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| ASTRAZENECA | 12 | 40 | +2,68 % | ||
| ALFA LAVAL | 1 | 7 | -1,95 % | ||
| SKANSKA | 1 | 4 | -3,14 % | ||
| ATLAS COPCO AB A | 1 | 3 | -2,34 % | ||
| ERICSSON | 1 | 3 | -2,27 % | ||
| TELE2 | 1 | 3 | -1,81 % | ||
| SVENSKA HANDELSBANKEN AB A | 1 | 3 | -1,11 % | ||
| H&M | - | 35 | -2,06 % | ||
| NORDEA BANK | - | 15 | -1,00 % | ||
| SWEDISH MATCH | - | 6 | -1,68 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:10 | Orange inks Ericsson mobile money deal | 4 | Mobile World Live | ||
| 12:58 | AstraZeneca's Imfinzi + chemotherapy tripled patient survival at three years in Phase III lung cancer study | 3 | Seeking Alpha | ||
| 12:47 | ASTRAZENECA PLC - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12:20 | UPDATE: AstraZeneca notes positive test results for new cancer drugs | 2 | Alliance News | ||
| 12:17 | Aktien Europa: Deutliche Verluste - Drohende Evergrande-Pleite belastet | 246 | dpa-AFX | PARIS/LONDON (dpa-AFX) - Ein drohender Zusammenbruch des chinesischen Immobilienkonzerns Evergrande hat am Montag auch Europas wichtigste Aktienmärkte deutlich ins Minus gezogen. Der EuroStoxx 50
... ► Artikel lesen | |
| 11:32 | UPDATE: AstraZeneca reports positive test results for new cancer drugs | 4 | Alliance News | ||
| 11:16 | FAS demands TELE2 to reduce tariffs | 2 | POST Online Media | ||
| 10:34 | Astrazeneca-Krebsmittel Enhertu reduziert Krankheitsforschritt um 72% | 138 | Dow Jones News | DJ Astrazeneca-Krebsmittel Enhertu reduziert Krankheitsforschritt um 72%
Von Anthony O. Goriainoff
LONDON (Dow Jones)--Der Pharmakonzern Astrazeneca hat mit seinem Krebsmedikament Enhertu einen... ► Artikel lesen | |
| 09:56 | TOP NEWS: AstraZeneca says Enhertu breast cancer drug improves survival | 4 | Alliance News | ||
| 09:46 | Atlas Copco Falls After BofA Downgrades to Neutral | 173 | PLX AI | (PLX AI) - Atlas Copco shares fell 2.4% in morning trading after Bank of America downgraded the stock to neutral from buy.• Price target cut to SEK 620 from SEK 650• This may be as good as it gets for... ► Artikel lesen | |
| 09:35 | Skanska tightens carbon targets | 1 | The Construction Index | ||
| 09:04 | AstraZeneca Enhertu Data Unprecedented, Should Boost Share Today, Analysts Say | 136 | PLX AI | (PLX AI) - AstraZeneca shares should outperform the market today after unprecedented data in its Enhertu breast cancer trial, analysts said. • Enhertu reduced the risk of disease progression or death... ► Artikel lesen | |
| 08:59 | AstraZeneca, Daiichi Sankyo breast cancer drug cuts risk of death by 72% | 6 | StockMarketWire | ||
| 08:46 | AstraZeneca: Enhertu Triples Progression-free Survival In Phase III DESTINY-Breast03 Trial | 140 | AFX News | LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) said detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu showed superior progression-free survival... ► Artikel lesen | |
| 08:36 | Alfa Laval to support Californian recycled water program | 1 | Cision News | ||
| 08:05 | AstraZeneca PLC: Enhertu reduced risk of disease progression by 72% | 3 | InvestEgate | ||
| 07:41 | Aktien: Gehäufte Impfdurchbrüche bei Covid-Vakzinen von Johnson & Johnson | Dennis Austinat | |||
| 07:22 | Knowit Shares Could More Than Double, Handelsbanken Says | 150 | PLX AI | (PLX AI) - Knowit shares have the potential to more than double, Handelsbanken analysts said, raising their price target for the stock to SEK 800. • Knowit last traded at SEK 334.50• Knowit is likely... ► Artikel lesen | |
| Sa | AstraZeneca: Imfinzi Plus Chemotherapy Triples Patient Survival At 3-yrs In ES-Small Cell Lung Cancer | 886 | AFX News | LONDON (dpa-AFX) - AstraZeneca Plc.'s (AZN, AZN.L) Imfinzi or durvalumab in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained... ► Artikel lesen | |
| Sa | AZN: Imfinzi Plus Chemotherapy Triples Patient Survival At 3-yrs In ES-Small Cell Lung Cancer | 3 | RTTNews |
Seite:
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
